Berlin-based blood analysis innovator aescolab secures new capital
Start-up uses AI for personalized health analyses
Advertisement
aescolab, a Berlin-based healthtech innovator that uses AI to deliver personalized health analysis and lifestyle recommendations based on blood values, has closed a new round of funding to accelerate its growth. The investment will help the company grow its presence in Germany and expand into international markets.
aescolab - Partner for blood analysis in BGM
© aescolab
The round was led by founding investor KRING, an ESG impact fund based in Copenhagen, which reaffirmed its confidence in aescolab's scalable, technology-driven approach to prevention and workplace health promotion.
"aescolab represents exactly the kind of meaning-driven, data-driven innovation we support," said Martin Kring, founder of KRING. "aescolab has proven that scalable, technology-enabled tools can lead to real improvements in human health - exactly the impact ESG capital should make."
Since its launch in May 2024, aescolab has already supported over 1,000 people and is actively working with several leading German companies to integrate blood-based health data into holistic employee health strategies.
The platform analyzes key blood biomarkers and creates personalized health reports - with clear, actionable recommendations for companies and individuals. The company's goal is to establish itself as a leading health partner for organizations that see the health of their employees as a strategic priority - while empowering employees to take responsibility for their own health.
"We want to be a reliable partner for forward-looking companies in Germany and throughout Europe," said Stephan Alexander Dreier, CEO of aescolab. "aescolab shows how AI and automation can solve one of the most pressing problems of the modern working world: Keeping people healthy and productive. For HR and OHM managers, we offer a new, data-driven approach to reduce sick days, increase energy levels and strengthen the employer brand. With this funding, we can scale our impact and help even more companies and employees to make health measurable, personalized and effective.
At the heart of aescolab's mission is the belief that understanding one's blood values is the foundation for sustainable health. With a focus on prevention, personalization and performance, the company positions itself as a strategic healthcare partner for forward-thinking employers - and as a promising player in the changing European healthtech market.
With the current financing round, aescolab reaches a total investment volume in the seven-digit range.
To support the next growth phase, aescolab brings on board several renowned investors and advisors from the fields of technology, strategy and healthcare:
- René Svendsen-Tune (former CEO GN Store Nord / Jabra; EVP, Nokia Networks) - as Chairman of the Board
- Jens Bjørn Andersen (former CEO, DSV) - Member of the Board of Directors
- Dr. Patrick Simon (former Senior Partner, McKinsey Germany; member of the Global McKinsey Health Institute Leadership Team)
- Dr. Cyrus Alamouti, experienced healthtech strategist and investor
- KRING, founding investor and ESG-oriented impact fund
"aescolab's model addresses a real and growing need - precisely, quickly and effectively," said René Svendsen-Tune. "The team, mission and technology are perfectly aligned - I look forward to actively shaping the next chapter as Chairman."
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Human–AI collectives make the most accurate medical diagnoses - Study highlights the potential for greater patient safety and more equitable healthcare
Ear wax as a possible screening medium for Parkinson’s disease
Making fibrosis visible – before it’s too late - With planned ETH spin-off to market maturity
New nanosensors make diagnostic procedures more sensitive - The nanosensors can be used to track reactions with invisible light, saving materials and time
Cyber Valley grants 500K to CELL’n’ROLL via 2023 Innovation Fellowship Program - Cyber Valley Community is advancing diagnostics for the future: Its goal is to create an innovative spin-off from the project after the funding term has ended
Blood diagnostics modelled on leeches - For all those who are afraid of needles: New device for taking blood samples uses microneedles and a suction cup instead of a large needle
AI personalises brain tumour therapy - Progress in the personalised treatment of brain tumours: AI identifies mutations
En Carta Diagnostics secures €1.5M to advance diagnostic kit platform for early Lyme disease detection - Groundbreaking patented molecular diagnostic kit poised to provide game-changing autonomous Lyme detection in minutes
Portable AI-based test kit to identify bacterial infections - Dutch scientist selected as a finalist for the Young Inventors Prize 2024: Her startup focuses on the most common types of infection
Altona Diagnostics announces leadership transition - New General Managers appointed
New MRI technology makes cancer visible at an early stage - MRI signal amplified 24,000-fold: University start-up QuantView develops highly sensitive contrast agent
